Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.0%

4 terminated/withdrawn out of 20 trials

Success Rate

77.8%

-8.7% vs industry average

Late-Stage Pipeline

10%

2 trials in Phase 3/4

Results Transparency

93%

13 of 14 completed trials have results

Key Signals

13 with results

Enrollment Performance

Analytics

Phase 2

9(47.4%)

Phase 1

7(36.8%)

Phase 3

2(10.5%)

Early Phase 1

1(5.3%)

19Total

Phase 2(9)

Phase 1(7)

Phase 3(2)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (20)

Showing 20 of 20 trials

NCT02405364Phase 2Completed

Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction

Role: collaborator

NCT01559935Phase 2Active Not Recruiting

Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma

Role: collaborator

NCT02360345Phase 1Completed

Phase I Trial of ONX-0801 Once Weekly or Alternate Weekly

Role: collaborator

NCT00813293Phase 2Completed

Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer

Role: collaborator

NCT03029234Phase 3Completed

Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma

Role: collaborator

NCT01813227Phase 2Completed

A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531

Role: collaborator

NCT01496118Phase 1Completed

Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma

Role: collaborator

NCT01402284Phase 2Completed

Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients

Role: collaborator

NCT01714609Phase 2Completed

The Effect of Sorafenib on Portal Pressure

Role: collaborator

NCT01775930Phase 2Completed

Carfilzomib in Refractory Renal Cell Carcinoma (RCC)

Role: collaborator

NCT01729104Phase 1Terminated

Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Role: collaborator

NCT02042950Phase 2Terminated

A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Role: collaborator

NCT01549431Phase 1Completed

Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma

Role: collaborator

NCT01234337Phase 3Completed

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Role: collaborator

NCT01969565Phase 2Terminated

Study of Carfilzomib in Combination w/Dexamethasone in Patients w/Newly Diagnosed Multiple Myeloma

Role: collaborator

NCT01029054Phase 1Completed

Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma

Role: collaborator

NCT01254890Phase 1Completed

Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome

Role: collaborator

NCT01585870Phase 1Completed

Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in Combination

Role: collaborator

NCT00999414Unknown

UARK 2009-32 Compassionate Use Study of Carfilzomib

Role: collaborator

NCT01337492Early Phase 1Terminated

Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT)

Role: collaborator

All 20 trials loaded